Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT Plus Second-generation Antiandrogen in Oligometastatic Castration-resistant Prostate Cancer
NCT07717268Phase 2Recruiting
- Start
- May 2024
- Primary completion
- May 2030
- Countries
- 1
01
Overview
A Phase 2 trial of enzalutamide, Abiraterone Acetate Tablets (I) in prostate cancer (PCa). Started May 2024; status: recruiting.
02
Drugs
enzalutamideAbiraterone Acetate Tablets (I)
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07717268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07717268.